Acute Impact of Apheresis on Oxidized Phospholipids in Patients with Familial Hypercholesterolemia

Overview

Journal J Lipid Res

Publisher Elsevier

Specialty Biochemistry

Date 2012 May 26

PMID 22628616

Citations 18

Authors

Kiyohito Arai

Alexina Orsoni

Ziad Mallat

Alain Tedgui

Joseph L Witztum

Eric Bruckert

Alexandros D Tselepis

M John Chapman

Sotirios Tsimikas

Affiliations

Soon will be listed here.

Abstract

We measured oxidized phospholipids (OxPL), lipoprotein (a) [Lp(a)], and lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) pre- and postapheresis in 18 patients with familial hypercholesterolemia (FH) and with low(∼10 mg/dl; range 10-11 mg/dl), intermediate (∼50 mg/dl; range 30-61 mg/dl), or high (>100 mg/dl; range 78-128 mg/dl) Lp(a) levels. By using enzymatic and immunoassays, the content of OxPL and Lp-PLA(2) mass and activity were quantitated in lipoprotein density fractions plated in microtiter wells, as well as directly on apoB-100, Lp(a), and apoA-I immunocaptured within each fraction (i.e., OxPL/apoB and Lp-PLA(2)/apoB). In whole fractions, OxPL was primarily detected in the Lp(a)-containing fractions, whereas Lp-PLA(2) was primarily detected in the small, dense LDL and light Lp(a) range. In lipoprotein capture assays, OxPL/apoB and OxPL/apo(a) increased proportionally with increasing Lp(a) levels. Lp-PLA(2)/apoB and Lp-PLA(2)/apoA-I levels were highest in the low Lp(a) group but decreased proportionally with increasing Lp(a) levels. Lp-PLA(2)/apo(a) was lowest in patients with low Lp(a) levels and increased proportionally with increasing Lp(a) levels. Apheresis significantly reduced levels of OxPL and Lp-PLA(2) on apoB and Lp(a) (50-75%), particularly in patients with intermediate and high Lp(a) levels. In contrast, apheresis increased Lp-PLA(2)-specific activity (activity/mass ratio) in buoyant LDL fractions. The impact of apheresis on Lp(a), OxPL, and Lp-PLA(2) provides insights into its therapeutic benefits beyond lowering apoB-containing lipoproteins.

Citing Articles

Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels.

Sosnowska B, Stepinska J, Mitkowski P, Bielecka-Dabrowa A, Bobrowska B, Budzianowski J Arch Med Sci. 2024; 20(1):8-27.

PMID: 38414479 PMC: 10895977. DOI: 10.5114/aoms/183522.

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN.

Reijman M, Kusters D, Groothoff J, Arbeiter K, Dann E, de Boer L medRxiv. 2023; .

PMID: 38014132 PMC: 10680892. DOI: 10.1101/2023.11.14.23298547.

Oxidized phospholipids in cardiovascular disease.

Tsimikas S, Witztum J Nat Rev Cardiol. 2023; 21(3):170-191.

PMID: 37848630 DOI: 10.1038/s41569-023-00937-4.

Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study.

Nurmohamed N, Collard D, Reeskamp L, Kaiser Y, Kroon J, Tromp T Atherosclerosis. 2022; 341:43-49.

PMID: 34995986 PMC: 8690577. DOI: 10.1016/j.atherosclerosis.2021.12.008.

PCSK9 Inhibition and Oxidized Phospholipids.

Bhatia H, Yeang C, Baruch A, Yang X, Stroes E, Tsimikas S J Am Coll Cardiol. 2021; 78(12):1288-1289.

PMID: 34531030 PMC: 10198455. DOI: 10.1016/j.jacc.2021.07.031.

References

Davidson M, Ballantyne C, Jacobson T, Bittner V, Braun L, Brown A . Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011; 5(5):338-67. DOI: 10.1016/j.jacl.2011.07.005. View

Goldberg A, Hopkins P, Toth P, Ballantyne C, Rader D, Robinson J . Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5(3 Suppl):S1-8. DOI: 10.1016/j.jacl.2011.04.003. View

Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K . Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1999; 82(12):1489-95. DOI: 10.1016/s0002-9149(98)00692-4. View

Orsoni A, Saheb S, Levels J, Dallinga-Thie G, Atassi M, Bittar R . LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection. J Lipid Res. 2011; 52(12):2304-2313. PMC: 3283261. DOI: 10.1194/jlr.P016816. View

Thompsen J, Thompson P . A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis. 2006; 189(1):31-8. DOI: 10.1016/j.atherosclerosis.2006.02.030. View

Bergmark C, Dewan A, Orsoni A, Merki E, Miller E, Shin M . A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008; 49(10):2230-9. DOI: 10.1194/jlr.M800174-JLR200. View

Raal F, Santos R, Blom D, Marais A, Charng M, Cromwell W . Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375(9719):998-1006. DOI: 10.1016/S0140-6736(10)60284-X. View

Marcovina S, Hobbs H, Albers J . Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem. 1996; 42(3):436-9. View

Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T . Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 1997; 95(1):76-82. DOI: 10.1161/01.cir.95.1.76. View

10.

Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F . Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007; 27(8):1788-95. DOI: 10.1161/ATVBAHA.107.145805. View

11.

Merki E, Graham M, Mullick A, Miller E, Crooke R, Pitas R . Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 2008; 118(7):743-53. DOI: 10.1161/CIRCULATIONAHA.108.786822. View

12.

Jaeger B, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E . Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009; 6(3):229-39. DOI: 10.1038/ncpcardio1456. View

13.

Ravandi A, Boekholdt S, Mallat Z, Talmud P, Kastelein J, Wareham N . Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res. 2011; 52(10):1829-36. PMC: 3173004. DOI: 10.1194/jlr.M015776. View

14.

Tsimikas S, Clopton P, Brilakis E, Marcovina S, Khera A, Miller E . Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 2009; 119(13):1711-9. PMC: 2782388. DOI: 10.1161/CIRCULATIONAHA.108.836940. View

15.

Gordon B, Kelsey S, Dau P, Gotto Jr A, Graham K, Illingworth D . Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. Am J Cardiol. 1998; 81(4):407-11. DOI: 10.1016/s0002-9149(97)00947-8. View

16.

Nordestgaard B, Chapman M, Ray K, Boren J, Andreotti F, Watts G . Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23):2844-53. PMC: 3295201. DOI: 10.1093/eurheartj/ehq386. View

17.

Mellwig K, Baller D, Gleichmann U, Moll D, Betker S, Weise R . Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis. 1998; 139(1):173-8. DOI: 10.1016/s0021-9150(98)00055-0. View

18.

Taleb A, Witztum J, Tsimikas S . Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med. 2011; 5(5):673-94. PMC: 3230643. DOI: 10.2217/bmm.11.60. View

19.

Davidson M, Corson M, Alberts M, Anderson J, Gorelick P, Jones P . Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008; 101(12A):51F-57F. DOI: 10.1016/j.amjcard.2008.04.019. View

20.

Tselepis A, Dentan C, Karabina S, Chapman M, Ninio E . PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol. 1995; 15(10):1764-73. DOI: 10.1161/01.atv.15.10.1764. View